Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
Open Access
- 2 October 2021
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (6) , 2027-2042
Abstract
Introduction Obesity, smoking, and alcohol consumption are prevalent in psoriasis patients and have been associated with increased disease severity and reduced treatment adherence and response. This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials compared the efficacy of brodalumab versus ustekinumab in psoriasis patients with aggravating and potentially treatment-confounding lifestyle risk factors. Methods This post hoc analysis evaluated complete skin clearance, as measured by a 100% reduction of Psoriasis Area and Severity Index (PASI100) and quality of life (QoL), as measured by a Dermatology Life Quality Index (DLQI) score of 0/1, by the presence of risk factors (obesity, tobacco or alcohol use). A competing risk model assessed cumulative incidence over 52 weeks with outcomes of PASI100 or inadequate response. Results This analysis included 929 patients (brodalumab 210 mg, n = 339; ustekinumab, n = 590) with moderate-to-severe psoriasis. At week 52, odds ratios (95% confidence intervals [CIs]) for complete clearance with brodalumab versus ustekinumab were 2.50 (1.14–5.46, P = 0.0186), 4.64 (2.80–7.69, P < 0.0001), 2.06 (1.25–3.40, P = 0.0045), and 2.55 (0.55–11.91, P = 0.2117) in patients with no, one, two, or three risk factors, respectively. Corresponding odds ratios (ORs) (95% CIs) for DLQI 0/1 with brodalumab versus ustekinumab were 1.72 (0.78–3.79, P = 0.1883), 2.49 (1.54–4.02, P < 0.0002), 1.57 (0.97–2.54, P = 0.0666), and 2.07 (0.45–9.57, P = 0.3438). The 52-week cumulative incidence of patients achieving PASI100 was consistently higher for brodalumab versus ustekinumab, regardless of number of risk factors (P < 0.0001 for one or two risk factors and P = 0.0029 for three risk factors). Conclusions Higher levels of complete skin clearance and QoL were achieved and maintained with brodalumab versus ustekinumab in patients with moderate-to-severe psoriasis, regardless of the presence of lifestyle risk factors. Clinical Trial Registration AMAGINE-2 (NCT01708603); AMAGINE-3 (NCT01708629).Keywords
Funding Information
- Amgen/Astrazeneca
- leo pharma a/s
This publication has 42 references indexed in Scilit:
- Psoriasis and smoking: a systematic review and meta‐analysisBritish Journal of Dermatology, 2014
- Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective studyJournal of Dermatological Treatment, 2013
- Adherence to medication in patients with psoriasis: a systematic literature reviewBritish Journal of Dermatology, 2012
- Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanismsBritish Journal of Dermatology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- Diet and Weight Loss as a Treatment for PsoriasisArchives of Dermatology, 2010
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Alcohol intake and treatment responsiveness of psoriasis: A prospective studyJournal of the American Academy of Dermatology, 1993
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988